Category Archives: Guest Blog

Preparing for Reentry: A Physician’s Story

By Daniel Laury, M.D. You would expect that, given a physician shortage, my goal of getting back into obstetrics would be supported and even welcomed.  The Association of American Medical Colleges expects that the US will have over 91,000 too few physicians by 2020.  I graduated medical school in 1988, completed an OBG residency in […]
Also posted in healthcare | Tagged , , | Leave a comment

Market Access in Ukraine

by Lana Sinichkina  and Leonid Cherniavskyi. On September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy. In line with the signed AA, the government has adopted a detailed implementation plan, which endorses for preparation and approval by the […]
Also posted in Europe, Global, healthcare, Op-Ed, pricing, Regulatory | Tagged , , , | Leave a comment

The Place of Digital in the Pharma Marketing Mix

By Mark Perlotto. Thirty-nine years ago this past June, an article appeared in BusinessWeek that offered readers what was for its time a startling degree of foresight. Four paragraphs down, just above their first historic mention of what they called “the paperless office,” the authors of “The Office of the Future” passed along a prediction […]
Also posted in Marketing, multimedia, social media, Strategy, Technology | Tagged | 1 Comment

Customer Engagement Isn’t Just About Physicians: It’s About Sales Reps Too

By Karl Tiedemann. Managing the pharma sales force has always been challenging. Reps are spread out geographically, often far from corporate offices, preventing them from taking part in the on-site activities and face-to-face interactions that typically foster a connection to the company. In order to help the sales force achieve their primary goal — educating […]
Also posted in Sales, Strategy | Tagged | 1 Comment

Healthcare Nonprofit Bans Genentech Reps

By Randi Hernandez, Pharmaceutical Technology. After a change in distribution strategy at Genentech, Ascension Health has prohibited sales representatives from the drug maker to solicit physicians at Ascension’s 1900 sites of care around the country. The ban is the result of a supply-chain move that routes three infused cancer medications—Avastin (bevacizumab), Rituxan (rituximab), and Herceptin […]
Also posted in healthcare, Sales | Tagged , , | Leave a comment
  • Categories

  • Meta